Xbrane Biopharma AB (XBRANE)

Stockholm
Currency in SEK
0.18
0.00(0.00%)
Closed·
XBRANE Scorecard
Full Analysis
Net income is expected to grow this year
Earnings results expected in 15 days
Fair Value
Day's Range
0.180.19
52 wk Range
0.130.36
Key Statistics
Edit
Prev. Close
0.18
Open
0.18
Day's Range
0.18-0.19
52 wk Range
0.13-0.36
Volume
3.86M
Average Volume (3m)
12.97M
1-Year Change
-23.4%
Book Value / Share
0.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XBRANE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.50
Upside
+177.78%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
No news in this category
Looks like there are no results in this news category

Xbrane Biopharma AB Company Profile

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn’s disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma. The company was incorporated in 2008 and is headquartered in Solna, Sweden.

Compare XBRANE to Peers and Sector

Metrics to compare
XBRANE
Peers
Sector
Relationship
P/E Ratio
−1.0x−2.9x−0.5x
PEG Ratio
−0.01−0.030.00
Price/Book
1.3x2.1x2.6x
Price / LTM Sales
1.4x6.6x2.9x
Upside (Analyst Target)
177.8%209.3%64.0%
Fair Value Upside
Unlock28.3%9.4%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.50
(+177.78% Upside)

Earnings

Latest Release
Feb 20, 2025
EPS / Forecast
-0.03 / 0.0054
Revenue / Forecast
-- / 176.20M
EPS Revisions
Last 90 days

People Also Watch

5.2680
ATORX
+0.38%
0.27
IMMNOV
0.00%
0.04
QLINEA
0.00%
7.21
SANION
+7.61%
18.00
SYNACT
-2.60%

FAQ

What Is the Xbrane Biopharma (XBRANE) Stock Price Today?

The Xbrane Biopharma stock price today is 0.18

What Stock Exchange Does Xbrane Biopharma Trade On?

Xbrane Biopharma is listed and trades on the Stockholm stock exchange.

What Is the Stock Symbol for Xbrane Biopharma?

The stock symbol for Xbrane Biopharma is "XBRANE."

What Is the Xbrane Biopharma Market Cap?

As of today, Xbrane Biopharma market cap is 275.79M.

What is Xbrane Biopharma Earnings Per Share?

The Xbrane Biopharma EPS is -0.22.

What Is the Next Xbrane Biopharma Earnings Date?

Xbrane Biopharma will release its next earnings report on 07 May 2025.

From a Technical Analysis Perspective, Is XBRANE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.